Kemin becomes majority shareholder in animal vaccine company MEVAC
Kemin Industries, the ingredient manufacturer, is growing its presence in the global vaccine market by becoming majority shareholder of Middle East for Vaccines (MEVAC), an animal vaccine manufacturer based in Cairo, Egypt.
“We entered into a partnership with MEVAC over a decade ago and are thrilled to become the majority shareholder,” said Chris Nelson, President and CEO, Kemin Industries.
First investing in the MEVAC in 2010, Kemin has increased its participation in the Egyptian-based company over the years. In 2019, Kemin increased its share in MEVAC and received the right to distribute its vaccines globally, outside the Arabic-speaking countries in the Middle East already served by MEVAC.
As part of its investment in MEVAC, Kemin has access to a modern vaccine plant with production and R&D capabilities to support future growth. UVAC, MEVAC’s sister company, has been established to produce foot-and-mouth disease and tissue-culture vaccines for animals, as well as human vaccines. Kemin also becomes a shareholder in MEVAC’s sister company, UVAC.